Viscoelastic Properties of Respiratory and Peripheral Muscles of COPD Patients
Comparison of Viscoelastic Properties of Respiratory Muscles and Peripheral Muscles in Chronic Obstructive Pulmonary Disease Patients With Healthy Subjects
1 other identifier
observational
60
1 country
1
Brief Summary
The aim of this study was to compare the viscoelastic properties of auxiliary respiratory muscles and peripheral muscles of chronic obstructive pulmonary disease patients with healthy subjects. Myotonometry was used to evaluate the viscoelastic properties of the muscles. The viscoelastic properties of the sternoclaidus mastoid, pectoralis major, upper trapezius, deltoid, biceps brachii, rectus femoris, gastrocinemius, and tibialis anterior muscles were evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2024
CompletedFirst Submitted
Initial submission to the registry
August 26, 2024
CompletedFirst Posted
Study publicly available on registry
August 30, 2024
CompletedNovember 22, 2024
January 1, 2024
3 months
August 26, 2024
November 21, 2024
Conditions
Outcome Measures
Primary Outcomes (7)
Respiratory functions (PEF)
Peak expiratory flow (PEF) were measured was evaluated with spirometry. It will be recorded as liters and expected percentage
1 Day
The Medical Research Council Scale
Patients simply indicate on the scale the level of activity that causes dyspnoea in them according to the activities between 0-4.
1 Day
The COPD Assessment Test
This statement describes a scale consisting of eight items, each with response values ranging from 0 to 5. The total score is calculated by summing the responses to all the items, resulting in a range from 0 to 40. A higher total score indicates a greater negative impact of the disease on the individual's quality of life and daily activities.
1 Day
Viscoelastic properties of muscles
The viscoelastic properties of the muscles (muscle tone (Hz), and elasticity (Relative), stiffness (N/m)) were measured using a hand-held myotonometer.
1 Day
Respiratory functions (FEV1)
In pulmonary function test was evaluated with spirometry. forced expiratory volume in the first second (FEV1);will be recorded as liters and expected percentage
1 Day
Respiratory functions (FVC)
In pulmonary function test was evaluated with spirometry. forced expiratory volume in the first second (FEV1);will be recorded as liters and expected percentage
1 Day
Respiratory functions (FEV1/FVC)
ratio of forced expiratory volume in the first second to vital capacity (FEV1/FVC) was evaluated with spirometry.
1 Day
Study Arms (2)
COPD group
Patients with COPD who presented to the chest diseases polyclinic and whose symptoms of cough, sputum and/or dyspnoea accompanied by tachypnoea and/or tachycardia had not worsened in the last 14 days were defined as 'Stable COPD group' \[
Control group
The control group was defined as those who did not have any systemic disease and who were normal at the end of the polyclinic examination who applied to the chest diseases polyclinic.
Eligibility Criteria
Patients with COPD who visited the chest diseases clinic and had symptoms of cough, sputum, and/or shortness of breath, along with tachypnea and/or tachycardia, that had not worsened in the past 14 days were classified as the 'Stable COPD group'.
You may qualify if:
- male gender,
- body mass index (BMI) between 18.5-29.9 kg/m2,
- stable COPD patients
You may not qualify if:
- being in the acute exacerbation period for COPD patients,
- having undergone any neurological, orthopaedic or thoracic surgery,
- presence of malignancy in any organ,
- presence of comorbidities affecting muscle atrophy (myasthenia gravis, muscular dystrophy, etc.).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Gaziantep İslamic Science and Technology University
Gaziantep, Şahinbey, 27000, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
August 26, 2024
First Posted
August 30, 2024
Study Start
January 1, 2024
Primary Completion
April 1, 2024
Study Completion
May 1, 2024
Last Updated
November 22, 2024
Record last verified: 2024-01